Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.51 |
| ▸ | TUBB | P07437 | 6/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 6/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 6/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 6/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 6/20 | 0.51 |
| ▸ | TUBB6 | Q9BUF5 | 6/20 | 0.51 |
| ▸ | TUBB2B | Q9BVA1 | 6/20 | 0.51 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 3/20 | 0.45 |
| ▸ | EDNRA | P25101 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2051287 | 0.86 | TUBB4A (0.50) | JAK2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2053166 | 0.85 | ICAM1 (0.39) | JAK2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4036538 | 0.85 | JAK2 (0.48) | JAK2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2052779 | 0.84 | PLK4 (0.44) | JAK2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2049205 | 0.83 | PNP (0.39) | JAK2CHEK2PARP1PKN1PKN2 | |
| SCHEMBL4035973 | 0.83 | KDM4E (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2053003 | 0.83 | PTGS2 (0.40) | JAK2PARP1CDC7TGFBR1GRM4 | |
| SCHEMBL2052754 | 0.82 | TUBB4A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4033989 | 0.81 | LMNA (0.39) | JAK2PARP1PKN1PKN2TGFBR1 | |
| SCHEMBL2050384 | 0.80 | PARP1 (0.45) | PARP1AURKATGFBR1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4691506-B2 | — | — | 2011-06-01 | — | — | JP | claimed |
| EP-1747220-B1 | SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | AVENTIS PHARMA INC (US) | 2009-04-15 | — | — | EP | claimed |
| CN-100439367-C | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMA INC (US) | 2008-12-03 | — | — | CN | claimed |
| US-7402672-B2 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2008-07-22 | — | — | US | claimed |
| EP-1747220-A1 | SUBSTITUTED 1H-PYRROLO 3,2-B, 3,2-C, AND 2,3-C¨PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | Aventis Pharmaceuticals Inc. (US) | 2007-01-31 | — | — | EP | claimed |
| CN-1906194-A | Substituted 1H-pyrrolo [3, 2-b, 3, 2-c and 2, 3-c ] pyridine-2-carboxamides and related analogs as inhibitors of casein kinase ie | AVENTIS PHARMA INC (US) | 2007-01-31 | — | — | CN | claimed |
| WO-2005061498-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | AVENTIS PHARMACEUTICALS INC. (US) | 2005-07-07 | — | — | WO | claimed |
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2005-06-16 | — | — | US | claimed |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | claimed |
| US-7626027-B2 | Substituted 1H-pyrrolo[2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase Iε | AVENTIS PHARMACEUTICALS INC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2009-07-30 | — | — | US | disclosed |
| EP-1747220-B1 | SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | AVENTIS PHARMA INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2008-09-18 | — | — | US | disclosed |
| US-20080200496-A1 | SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie | AVENTIS PHARMACEUTICALS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20020115689-A1 | Administering a combination of an HMB-CoA reductase inhibitor and a selective COX-2 inhibitor to prevent, reduce the risk of, delay the onset of, or treat Alzheimer's disease | WALDSTREICHER JOANNE (US) | 2002-08-22 | — | — | US | disclosed |
| US-20020016342-A1 | Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor | SCOLNICK EDWARD (US) | 2002-02-07 | — | — | US | disclosed |
| US-20010031757-A1 | Method for treating inflammatory diseases by administering a thrombin inhibitor | SHAFER JULES (US) | 2001-10-18 | — | — | US | disclosed |
| US-6245797-B1 | ADMINISTERING MIXTURE OF ENZYME INHIBITORS | MERCK & CO., INC. | 2001-06-12 | — | — | US | disclosed |
| US-6232315-B1 | SUCH AS 3-(2-PHENYLETHYLAMINO)-6-METHYL-1-(2-AMINO-6-METHYL -5-METHYLENE-CARBOXAMIDOMETHYLPYRIDINYL)-2-PYRAZINONE;TREATING NEPHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, GLOMERULONEPHRITIS, AND SACOIDOSIS | MERCK & CO., INC. | 2001-05-15 | — | — | US | disclosed |
| US-6136804-A | ANTIISCHEMIC AGENTS, ANTITHROMBOTIC AGENTS, THROMBOTIC OCCLUSION AND ANTIPLATELET AGENT | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | HDAC2, HDAC9, HDAC1 | JAK2 787/4885TUBB4A 2515/4885TUBB 2462/4885 |
| US-20010031757-A1 | Method for treating inflammatory diseases by administering a thrombin inhibitor | PTGIS, PTMS, PTGS1 | JAK2 326/4885TUBB4A 4280/4885TUBB 4151/4885 |
| US-20080200496-A1 | SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie | CSNK1E, CSNK1G3, CSNK2A3 | JAK2 477/4885TUBB4A 1772/4885TUBB 1259/4885 |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | PTGS1, PTGS2, PTGES2 | JAK2 1082/4885TUBB4A 4711/4885TUBB 4641/4885 |
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | CSNK2A3, PACSIN2, CSNK1G3 | JAK2 169/4885TUBB4A 2771/4885TUBB 2093/4885 |
| US-20020115689-A1 | Administering a combination of an HMB-CoA reductase inhibitor and a selective COX-2 inhibitor to prevent, reduce the risk of, delay the onset of, or treat Alzheimer's disease | HMGCR, ACACB, IDH3B | JAK2 4874/4885TUBB4A 1325/4885TUBB 1211/4885 |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | HDAC2, HDAC9, HDAC1 | JAK2 787/4885TUBB4A 2515/4885TUBB 2462/4885 |
| US-20020016342-A1 | Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor | PTGES2, PTGS2, PTGER1 | JAK2 569/4885TUBB4A 4592/4885TUBB 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.